Importantly, no additional increase in virus yield was observed on Ruxolitinib treatment of IFI16 or PML depleted cells (Fig 8D), indicative of an impaired innate immune response in these cells during HSV-1 ICP0-null mutant infection. Here, IFI16 is linked to infection.